TRANSCRIPT TO FOLLOW
The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.
With central banks across the globe engaged in extensive QE programmes, this has put pressure ...
BlackRock's UK equity team explains why they are including growth stocks in their income fund
Silver Rated Franklin fund manager Colin Morton on the benefits of Brexit on UK equities, whet...
The current investment climate is tough for those seeking an income from their savings. We tal...
Data from Morningstar Direct reveals three Bronze Rated investment trusts providing some of th...
Mining companies are operating in a challenging environment but could now be the time to top up o...
THE WEEK: Morningstar columnist Rodney Hobson provides two pieces of advice to George Osborne, an...
Businesses that have competitive advantages within their industry are good candidates for dividen...
Morningstar reveals the top 10 best performers over the last five years
Morningstar OBSR reveals the top funds for investors seeking exposure to European equities
The bank also announced a deal with Metro Bank, raised its guidance, and increased its dividends
With revenue growth, increased operating margins, but a high valuation, here’s what we think of N...
We'll be watching iPhone revenue, gross margins, and services growth when Apple reports its earni...
Despite growth, Morningstar's Fair Value Estimate for the consumer goods giant stock is unchanged
Morningstar analysts think the UK's biggest company has a well-positioned broad drug portfolio wh...
Security Name | Price | Change (%) | Morningstar Rating |
---|---|---|---|
TB Saracen Global Income and Growth BAcc | 314.32 GBP | -1.85 |
Emma Wall is former Senior International Editor for Morningstar